Atrial Fibrillation Paroxysmal Clinical Trial
— PVACOfficial title:
Isolation of Pulmonary Veins With PVAC GOLD in Elderly Patients
Verified date | July 2022 |
Source | University of Sao Paulo General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
It is a prospective, randomized and double-blind clinical trial involving an invasive technique for isolation of pulmonary veins (PVAC gold) in relation to clinical treatment during an one year of segment. The patients included have paroxysmal atrial fibrillation (aged 65 years and older) refractory to antiarrhythmic treatments that do not have structural and / or ischemic heart diseases. This trial employed quality of life scores prior to the study and during the sixth and twelfth month of the segment, electrocardiograms and holter of 24 hours. The proposed imaging tests was the transesophageal echocardiogram before each procedure. The cerebral MRI was performed in the 24 hours post invasive procedure and Angio-tomography of the pulmonary veins in the 6-month segment.
Status | Completed |
Enrollment | 60 |
Est. completion date | June 3, 2022 |
Est. primary completion date | February 20, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility | Inclusion Criteria: - Indication for isolation of pulmonary veins - Age >= 65 years old - Association with the following characteristics: 1. Symptomatic Atrial Fibrillation; 2. Sinusal Rhythm maintenance failure for at least 1 Antiarrythmic Drugs; 3. Diagnosis of Atrial Fibrilation on resting eletrocardiogram and/or 24h Holter. Exclusion Criteria: - Prior Atrial Fibrillation ablation; - Atrial Fibrillation permanent and/or persistent; - Left atrial size > 55 mm; - Mechanical prothetic mitral valve replacement; - Presence of atrial thrombus; - Cardiac invasive procedure < 90 days; - Cerebral embolism < 6 months; - Hypertrophic cardiomyopathy; - Contraindications to antiocoagulation and cerebral MRI. |
Country | Name | City | State |
---|---|---|---|
Brazil | Arrhythmia Clinical Unit - Instituto do Coração - HCFMUSP | Sao Paulo | SP |
Lead Sponsor | Collaborator |
---|---|
University of Sao Paulo General Hospital | Medtronic |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recurrence of atrial fibrillation | Recurrence of atrial fibrillation during 1 year of follow-up | 1 year after ablation | |
Secondary | Occurrence of Asymptomatic Cerebral Embolism | Occurrence of Asymptomatic Cerebral Embolism during 1 year of follow-up | 1 year of follow-up | |
Secondary | Esophageal Ulcer | Esophageal Ulcer documented by Esophagus-gastro-duodenoscopy after ablation procedure | 24 hours after pulmonary vein isolation | |
Secondary | Quality of Life Assessment | Quality of Life in Atrial Fibrillation Questionnaire Score | 1 year after ablation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06085014 -
Clinical and Electrophysiological Predictors of Arrhythmic Recurrence in Patients With Paroxysmal AF Undergoing First Ablation Procedure of AF by Pulmonary Vein Isolation
|
||
Recruiting |
NCT03724383 -
Atrial Fibrillation Lifestyle Project
|
N/A | |
Active, not recruiting |
NCT04544397 -
Outcomes of Second Generation Laser Balloon Ablation for Atrial Fibrillation
|
||
Not yet recruiting |
NCT05940597 -
Pulsed Field Ablation vs Cryoablation In Paroxysmal Atrial Fibrillation
|
N/A | |
Not yet recruiting |
NCT04447300 -
Outcomes of High Power Application in Catheter Ablation of Paroxysmal Atrial Fibrillation Guided by Unipolar Signal Modification.
|
N/A | |
Recruiting |
NCT05251545 -
Randomized Trial: High Power Short Duration Versus Ablation Index
|
N/A | |
Recruiting |
NCT05883631 -
RESOLVE-AF: Clinical Evaluation of the Ablacathâ„¢ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
|
N/A | |
Not yet recruiting |
NCT04600713 -
Physiotherapist-led Exercise Within Cardiac Rehabilitation and Paroxysmal Atrial Fibrillation and COVID-19.
|
N/A | |
Enrolling by invitation |
NCT05725187 -
Prospective Validation Study of AI-based Prediction Algorithm for the Prediction of Paroxysmal Atrial Fibrillation
|
||
Recruiting |
NCT04606693 -
Value of Screening and Treatment of SAHS in the Management of AF Ablation Candidates
|
N/A | |
Recruiting |
NCT05328882 -
Early Recurrences of Atrial Arrhythmias and Their Impact on Late Recurrence After Pulmonary Vein Isolation With Pulsed Field Ablation of Paroxysmal Atrial Fibrillation
|
||
Recruiting |
NCT04342312 -
Intensive Molecular and Electropathological Characterization of Patients Undergoing Atrial Fibrillation Ablation
|
||
Recruiting |
NCT05549752 -
Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia
|
Phase 3 | |
Completed |
NCT03323099 -
Individualized Studies of Triggers of Paroxysmal Atrial Fibrillation
|
N/A | |
Completed |
NCT05461859 -
Cardioneuroablation for the Treatment of Vagally-mediated Atrial Fibrillation.
|
||
Enrolling by invitation |
NCT04634461 -
The Relationship Between Panic Attack Symptoms and Atrial Fibrillation Episodes.
|
||
Recruiting |
NCT06392932 -
Esophageal Temperature During PVI Using Q-DOT Micro
|
N/A | |
Not yet recruiting |
NCT06364215 -
Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation
|
N/A | |
Recruiting |
NCT05292209 -
RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring
|
Phase 2 | |
Completed |
NCT04511520 -
Efficacy of Personalized Exercise Program and Trimetazidine in Rehabilitation of Patients After RFA of AF
|
N/A |